Integra LifeSciences (NASDAQ:IART) Issues Earnings Results, Beats Expectations By $0.01 EPS

Integra LifeSciences (NASDAQ:IART) released its quarterly earnings data on Monday. The life sciences company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01, Briefing.com reports. The business had revenue of $418.20 million during the quarter, compared to the consensus estimate of $413.07 million. Integra LifeSciences had a return on equity of 13.95% and a net margin of 1.51%. The firm’s revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.71 earnings per share.

Integra LifeSciences Trading Down 1.5 %

Shares of IART opened at $25.03 on Wednesday. The company has a debt-to-equity ratio of 1.15, a quick ratio of 3.35 and a current ratio of 4.68. Integra LifeSciences has a 52-week low of $22.36 and a 52-week high of $46.09. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of 50.06, a PEG ratio of 1.12 and a beta of 1.11. The business’s fifty day moving average is $29.67 and its 200-day moving average is $33.52.

Insider Activity at Integra LifeSciences

In other news, Chairman Stuart Essig acquired 52,641 shares of the business’s stock in a transaction that occurred on Thursday, May 23rd. The shares were bought at an average price of $28.49 per share, with a total value of $1,499,742.09. Following the acquisition, the chairman now directly owns 487,922 shares in the company, valued at approximately $13,900,897.78. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Morgan Stanley upped their price objective on Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a report on Monday, July 15th. Citigroup cut Integra LifeSciences from a “neutral” rating to a “sell” rating and reduced their price target for the company from $30.00 to $23.00 in a research report on Tuesday. Bank of America reduced their price target on Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating for the company in a research report on Tuesday, May 7th. JMP Securities reduced their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday. Finally, StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Monday, May 13th. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $29.25.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.